Thomas E Serena
Serena Group™, USA
Thomas E Serena is the Founder and Medical Director of Serena Group™, a family of wound, hyperbaric and research companies. He completed his residency in Surgery at the Hershey Medical Center. To date he has opened and operates wound care centers across the United Sates and globally. He has been the Lead or Principal Investigator in over 100 clinical trials and is recognized internationally as an expert in the field of Wound Healing. He has more than 100 published papers and has given more than 1000 invited lectures throughout the world. He has been a Member of the Board of Directors of the Wound Healing Society and served two terms on the Board of the Association for the Advancement of Wound Care (AAWC) and is at present the President-Elect. He has also been Vice-President of the American College of Hyperbaric Medicine and President of the American Professional Wound Care Association.
Clinical research has been an essential component of SerenaGroup’s® Center-of-Excellence model for wound and hyperbaric centers. We are one of the world’s leaders in clinical research in wound healing and hyperbaric medicine. In recent years, we realized that a comprehensive research program must include translational research. In 2015 SerenaGroup Innovation™ opened a laboratory at Northeastern Ohio Medical School to conduct preclinical and bench studies in wound healing. We also partnered with several university preclinical research groups. An unexpected shift in the mindset of our PhDs and clinical investigators occurred in a relatively short period of time: information began to flow from the lab into the clinic and back again. At our conferences, clinicians expressed a desire for new therapies and improved treatments. The research team focused on these unsolved problems. The result has been improved treatment algorithms, a better understanding of the science behind existing treatment modalities and most importantly, innovation. The research team has filed numerous patents as a result of these efforts. Clearly, a translational culture improves patient care and drives innovation.